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Nowadays, the popularity of medicinal herbs (MHs) and other natural

genus as American ginseng (Panax quinquefolius) or Chinese ginseng

products has increased dramatically worldwide. Consumers may use

(Panax ginseng) but possesses different bioactive constituents and has

MHs as an alternative or complementary medicine to conventional

no effect on CYP3A4.3 Therefore, it should not interact with atorva-

drugs. Recently, we read two articles published in the British Journal of

statin metabolism. It is possible that concomitant use of Eleuthero

Clinical Pharmacology (BJCP) describing drug-induced liver injury (DILI)

and/or milk thistle with other medications taken by the patient was

resulting in toxicity from the concomitant use of conventional drugs

responsible for the observed DILI.

and MHs.1,2

Another case of a potential HDI was described for a patient con-

The first article describes a patient treated with oral crizotinib

comitantly using erlotinib with hibiscus (Hibiscus sabdariffa) tea,

who developed signs of liver distress. At that time, the patient pres-

known for its anti-inflammatory and anti-tumour properties.4 The

ented with dramatically elevated levels of alanine aminotransferase

patient developed cutaneous lesions shortly after drinking the hibis-

(20 × ULN). Histological lesions suggested acute drug-induced hepati-

cus tea. Discontinuation of the tea led to the rapid improvement of

tis. In addition to crizotinib, the patient had consumed large quantities

the cutaneous lesions. The analysis of potential HDI demonstrated

of hot water with honey, lemon juice and grated ginger roots (Zingiber

that hibiscus inhibits CYP3A4 and CYP1A2, two enzymes responsible

officinale) for non-medical purposes. A detailed analysis of potential

for erlotinib metabolism.

herb–drug interaction (HDI) revealed that ginger inhibits the activity

In the case reports described above, patients self-prescribed

of CYP3A4, CYP2C9 and P-gp enzymes, enzymes responsible for

MHs. Self-administered MHs like cassia (Cinnamomum cassia), chapar-

crizotinib metabolism. Elevated trough concentrations of crizotinib

ral (Larrea tridentate), gotu kola (Centella asiatica), comfrey (Symphytum

strengthen the opinion that a ginger–crizotinib drug interaction

officinale) and saw palmetto (Serenoa repens) are also capable of pro-

resulted in a potentiation of the crizotinib hepatotoxicity.

moting liver toxicity.5 Numerous reports describe MH-associated

The second case outlining a potential HDI was reported by Laube
2

nephrotoxicity.6 These MHs include Taxus celebica, Tripterygium regelii,

and Liu. An elderly patient presented with DILI after a long history of

Clematis chinensis, Cassia obtusifolia, Gardenia jasminoides, Croton

using atorvastatin. The patient used a dietary supplement containing

caudatus, Stephania tetrandra, Strychnos nux-vomica and many others.

Siberian ginseng (Eleuthero, Eleutherococcus senticosus (Rupr. &

Aristolochic acid and the nephrotoxic alkaloids derived from these

Maxim.)) and silymarin, a bioactive compound found in milk thistle (Sil-

plants are often implicated as constituents that cause kidney damage.

ybum marianum (L.) Gaertn.), one week before elevated levels of ami-

Chinese Traditional Medicine is often used as complementary or

notransferases were noticed (12–17 ULN). The authors proposed that

supportive medicine for the treatment of oncological patients.7 It has

‘ginseng’ induced DILI via inhibition of CYP3A4, the enzyme responsi-

been reported that these MHs, as well as dietary supplements, are

ble for atorvastatin metabolism. Eleuthero belongs to the same Parax

responsible for 26.8% of DILI hospitalizations,8 but it is not clear how
many of these patients self-prescribed MHs.7 So and colleagues

[Correction added on 16 September 2020, after first online publication: Article title has been
corrected in this online issue version.]
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reported that their preliminary data indicate that 25% of patients with
solid tumours were prescribed Chinese Traditional Medicines in
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addition to conventional treatments.7 Very few patients who were
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cines presented with DILI. Additionally, there were no differences in
the severity of DILI between groups. This may suggest that the majority of reported cases of DILI were associated with self-prescribed use
of MHs.
Until recently, a few RCT have been reported that question safety
and efficacy of MHs like ginger, Eleuthero or silymarin.9–11 Saneei
Totmaj et al. performed a systematic literature review of RCT
reporting effectiveness of ginger in chemotherapy-induced nausea
and vomiting and improvement12 and concluded that ginger could
reduce nausea and vomiting in breast cancer patients receiving chemotherapy. In 1986, RCT reported that Eleuthero could stimulate
immunity in cancer patients receiving radiation and chemotherapy.13
However, there is a growing interest among consumers regarding the
use of MHs and dietary supplements, as well as an increase in MHdrug interactions reported by physicians. This necessitates the initiation of new RCT of MHs, especially for categories of patients like
oncological patients. This RCT should determine whether or not MHs
commonly used by these patients are safe when used concurrently
with conventional treatment.
This brief snapshot of reported MH toxicity indicates that concomitant use of MHs with conventional drugs may result in severe
adverse reactions leading to the potentiation of conventional drug
toxicity. Unfortunately, many consumers consider MHs to be safe
alternatives to conventional drugs and do not think that taking something that is labelled as an MH can harm them. This is becoming a
growing area of concern for clinical pharmacologists as ~50% of the
adult population use MHs or dietary supplements.
Many patients, including oncological patients, self-prescribe MHs,
and dietary supplements to ameliorate side effects of conventional
drugs or treat their diseases when conventional drugs are not effective. Providers and clinical pharmacologists should be familiar with
HDIs that may occur following the concomitant use of MHs and conventional drugs, as well as the adverse reactions associated with MHs.
When providers choose a treatment strategy for a patient using MHs,
he/she should consider whether the expected benefits of the MH use
would exceed possible risks.
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